info@oncologyventure.com

2X Oncology Announces Validation of Drug Response Predictor (DRP) for its PARP Inhibitor 2X-121

— Developed DRP Successfully Identified Responders and Non-responders to Treatment with 2X-121 in 13-Patient Blinded Study —  Cambridge, MA – August...